Compare SGMO & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SGMO | MOLN |
|---|---|---|
| Founded | 1995 | 2004 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 155.1M | 157.8M |
| IPO Year | 2000 | 2021 |
| Metric | SGMO | MOLN |
|---|---|---|
| Price | $0.50 | $4.57 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 7 | 1 |
| Target Price | ★ $4.71 | $4.00 |
| AVG Volume (30 Days) | ★ 9.3M | 6.0K |
| Earning Date | 11-06-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $32,875,000.00 | N/A |
| Revenue This Year | $1.37 | N/A |
| Revenue Next Year | N/A | $1,000.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.38 | $3.36 |
| 52 Week High | $2.84 | $5.99 |
| Indicator | SGMO | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 51.55 | 61.82 |
| Support Level | $0.42 | $3.99 |
| Resistance Level | $0.55 | $4.61 |
| Average True Range (ATR) | 0.05 | 0.16 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 67.23 | 85.71 |
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.